J&J will proceed with a $2.3 billion takeover bid for Crucell

12/2/2010 | Wall Street Journal, The

Johnson & Johnson plans to go ahead with a $2.3 billion cash offer to acquire the rest of Crucell. The drug giant has left open a possibility for renegotiation in case the biotech firm's manufacturing problems in South Korea worsen. J&J expects Dutch regulators to decide on the transaction ahead of Crucell's shareholder meeting Dec. 10.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD